Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to…
Lilly committed up to $1.9B (CHF 1.89B) including $80.4M upfront, $50M convertible note, and ~$1.7B in milestones for AC Immune's Morphomer Tau small-molecule…
Subsequent $12.5M expansion payment as the Morphomer Tau small-molecule asset moved closer to clinic — analysts treated the follow-on payment as validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly licensed AC Immune's Tau Morphomer small molecule discovery program for Alzheimer's disease and other neurodegenerative diseases. AC Immune received CHF 80M upfront ($80M) plus a CHF 50M equity investment, with up to CHF 1.7B (~$1.8B) in development, regulatory and commercial milestones plus tiered royalties on net sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / AC Immune SA (this deal) | 2019 | $1.9B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2019 deals · Eli Lilly and Company deals · Neurology deals